Severe acute respiratory syndrome coronavirus

Eurofins Viracor announces the launch of cPass™ Coronavirus SARS-CoV-2 Neutralizing Antibody Testing

Retrieved on: 
Monday, April 5, 2021
Zoonoses, Sarbecovirus, Medical specialties, Medicine, Health, COVID-19, Occupational safety and health, Public health, Eurofins Scientific, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome coronavirus, Neutralizing antibody

LEE'S SUMMIT, Mo., April 5, 2021 /PRNewswire/ --Eurofins Viracor, a leader in infectious disease testing for over 35 years, announces the launch of cPass Coronavirus SARS-CoV-2 Neutralizing Antibody test.

Key Points: 
  • LEE'S SUMMIT, Mo., April 5, 2021 /PRNewswire/ --Eurofins Viracor, a leader in infectious disease testing for over 35 years, announces the launch of cPass Coronavirus SARS-CoV-2 Neutralizing Antibody test.
  • The cPass Coronavirus SARS-CoV-2 Neutralizing Antibody test is specific to SARS-CoV-2 neutralizing antibodies.
  • The cPass Coronavirus SARS-CoV-2 Neutralizing Antibody test joins the robust menu of RT-PCR, IgG and, IgM testing to help identify active or prior COVID-19 cases.
  • Eurofins Viracor is a subsidiary of Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services.

New Research Findings Published in Pharmaceuticals Identify Novel Peptoids with Potent Antiviral Activity Against HSV-1 and SARS-CoV-2

Retrieved on: 
Monday, April 5, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Other Health, Medical specialties, Medicine, Clinical medicine, Sarbecovirus, Antiviral drugs, Antimicrobial peptides, Immune system, Immunology, Herpes simplex virus, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Antimicrobial

Titled Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial Peptoids , the research findings demonstrate that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2.

Key Points: 
  • Titled Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial Peptoids , the research findings demonstrate that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2.
  • Their antiviral activity was studied and tested at the University of Louisville with financial support from Maxwell Biosciences .
  • To determine whether the peptoids exhibited activity against enveloped viruses, the researchers tested the in vitro inhibitory activity of peptoids MXB-4 and MXB-9 against SARS-CoV-2.
  • Since antimicrobial peptides such as LL-37 exhibit potent activity against HSV-1 [ 36 ], their potential as antiviral preventive or therapeutic agents is significant.

New CaviWipes 2.0 Earns EPA’s Emerging Viral Pathogen Claim; Proves Effective Against 42 Pathogens Including SARS-CoV-2 and Candida Auris

Retrieved on: 
Monday, April 5, 2021
Medical Supplies, Retail, Health, Infectious diseases, Home Goods, Specialty, Epidemiology, Health sciences, Health, Medical specialties, Infectious diseases, Zoonoses, Pandemics, Virus, Disinfectant, Severe acute respiratory syndrome coronavirus, Infection, Pathogen

View the full release here: https://www.businesswire.com/news/home/20210405005008/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210405005008/en/
    CaviWipes 2.0 surface disinfectant wipes are effective against 42 pathogens, including SARS-CoV-2, and are fully qualified for the Environmental Protection Agencys (EPA) Emerging Viral Pathogen Claim.
  • With the approval of an emerging viral pathogen claim, EPA-registered disinfectant products can make specific claims against an outbreak virus.
  • EPAs Emerging Viral Pathogen claim indicates that CaviWipes 2.0 meets current and future infection prevention needs for all virus types, including enveloped, large and small non-enveloped viruses.
  • 1 CaviWipes 2.0 meets the criteria to make claims against emerging viral pathogens from the Enveloped Viruses, Large and Small Non-Enveloped Viral categories.

EUROIMMUN Launches SARS-CoV-2 NeutraLISA Assay to Determine the Neutralizing Capacity of Anti-SARS-CoV-2 Antibodies

Retrieved on: 
Thursday, April 1, 2021
Biotechnology, Medical devices, Infectious diseases, Health, Pharmaceutical, Sarbecovirus, Medical specialties, Medicine, Zoonoses, Bat virome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, COVID-19, ELISA, Severe acute respiratory syndrome–related coronavirus, Middle East respiratory syndrome–related coronavirus

EUROIMMUN , a PerkinElmer, Inc. Company, today announced the launch of the SARS-CoV-2 NeutraLISA assay, a surrogate neutralization test intended for the detection of neutralizing antibodies against SARS-CoV-2, the pathogen causing COVID-19.

Key Points: 
  • EUROIMMUN , a PerkinElmer, Inc. Company, today announced the launch of the SARS-CoV-2 NeutraLISA assay, a surrogate neutralization test intended for the detection of neutralizing antibodies against SARS-CoV-2, the pathogen causing COVID-19.
  • However, if the RBD is blocked by specific antibodies formed during immune response, the virus cannot continue to infect and proliferate within the human body.
  • The EUROIMMUN SARS-CoV-2 NeutraLISA imitates this natural process by determining the inhibitory effect of antibodies capable of hampering the interaction between biochemically produced RBD and ACE2.
  • The SARS-CoV-2 NeutraLISA assay supplements EUROIMMUNs existing CE-marked QuantiVac ELISA and SARS-CoV-2 Interferon-gamma Release Assay which is expected to be available with CE mark soon.

NanoString's GeoMx Digital Spatial Profiler Reveals Insights into COVID-19 in Two New Nature Publications

Retrieved on: 
Wednesday, March 31, 2021
Science, Biotechnology, Research, Health, Data management, Infectious diseases, Technology, Genetics, Sarbecovirus, Respiratory diseases, Zoonoses, Animal diseases, Bat virome, Data mining, Identity management, Profiling, COVID-19, Profiler, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced that two peer-reviewed publications using the GeoMx Digital Spatial Profiler have been published in Nature and Nature Communications.

Key Points: 
  • NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced that two peer-reviewed publications using the GeoMx Digital Spatial Profiler have been published in Nature and Nature Communications.
  • These papers describe the use of Digital Spatial Profiling (DSP) technology to investigate SARS-CoV-2 infection and drive diagnostic, prevention, and treatment strategies.
  • The GeoMx DSP was used to profile lung tissue collected on autopsy from patients who had succumbed to COVID-19 infection.
  • The companys GeoMx Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.

AcademicInfluence.com Welcomes Editor Dave Tomar, Expert on Cheating, As He Addresses COVID-19's Impact on the Student Cheating Surge

Retrieved on: 
Monday, March 29, 2021
Sarbecovirus, Zoonoses, Articles, Animal diseases, Bat virome, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome coronavirus, Pandemic, Severe acute respiratory syndrome, Ed Dante, Middle East respiratory syndrome–related coronavirus, Coronavir

Sadly, cheating is rampant at all levels of education, and it may have an ally in an unlikely source: SARS-CoV-2, the novel coronavirus.

Key Points: 
  • Sadly, cheating is rampant at all levels of education, and it may have an ally in an unlikely source: SARS-CoV-2, the novel coronavirus.
  • Today, AcademicInfluence.com tackles this challenge of pandemics and cheating with its own triple threat, naming Dave Tomar its new Managing Editor.
  • The article explores student despair as a core driver of cheating at a time when students have never been more vulnerable or at risk.
  • AcademicInfluence.com is a part of the EducationAccess group, a family of sites dedicated to lifelong learning and personal growth.

COVID-19 Antibody Tests For Variants Now Available Worldwide

Retrieved on: 
Monday, March 29, 2021
Coronaviridae, Sarbecovirus, SARS-CoV-2, Variants of SARS-CoV-2, Zoonoses, Occupational safety and health, Atypical pneumonias, COVID-19, 501.V2 variant, Severe acute respiratory syndrome coronavirus, Lineage B.1.1.7, Lineage P.1

(MSD) today announced the commercial release of its V-PLEX Serology Panels for SARS-CoV-2 variants.The release includes panels that test for important variants spreading worldwide, including the B.1.1.7, B.1.351, and P1 variants, referred to in the news as the U.K., South African, and Brazilian variants, respectively.

Key Points: 
  • (MSD) today announced the commercial release of its V-PLEX Serology Panels for SARS-CoV-2 variants.The release includes panels that test for important variants spreading worldwide, including the B.1.1.7, B.1.351, and P1 variants, referred to in the news as the U.K., South African, and Brazilian variants, respectively.
  • Variants of SARS-CoV-2 may evade immunity or increase transmission, increasing COVID-19 cases and potentially diminishing the impact of vaccines.MSD's new V-PLEX Serology Panels help scientists understand how SARS-CoV-2 variants respond to antibodies generated by vaccination or natural infection.
  • Jacob Wohlstadter, President and Chief Executive Officer, remarked, "The emergence of certain new SARS-CoV-2 variants presents a challenge to the worldwide effort to combat COVID-19.We are grateful to the many organizations studying and developing new vaccines for important variants.
  • "These new tests will accelerate the timelines for developing vaccines against variants," said James Wilbur, Chief Business Officer of MSD.

Escher Biomedical Diagnostics Announces BT-MED® COV19 Test for Detection of COVID-19 Virus Infection in Saliva Samples

Retrieved on: 
Monday, March 29, 2021
Emergency Use Authorization, Food and Drug Administration, COVID-19, Severe acute respiratory syndrome coronavirus, Health, Articles, DiaSorin, COVID-19 testing

AUSTIN, Texas, March 29, 2021 (GLOBE NEWSWIRE) -- Escher Biomedical Diagnostics, LLC announced that its Escher BT-MED COV19 Saliva Test has been accepted by FDA as a Notification under SectionIV.C of the Emergency Use Authorization program.

Key Points: 
  • AUSTIN, Texas, March 29, 2021 (GLOBE NEWSWIRE) -- Escher Biomedical Diagnostics, LLC announced that its Escher BT-MED COV19 Saliva Test has been accepted by FDA as a Notification under SectionIV.C of the Emergency Use Authorization program.
  • The BT-MED COV19 Test system is a high-throughput molecular method for detecting infection by the SARS-CoV-2 virus in specimens of saliva from individuals suspected of COVID-19 by their healthcare provider.
  • Through this Notification, Escher indicates its intent to distribute the COVID-19 virus test in the US while FDA review of the EUA request is pending.
  • The novel approach developed by Biotrack BV allows fast and accurate detection of the COVID-19 virus within infected human cells that appear in saliva," stated Phil Speros of Escher.

DeciBio Analytics Launches DxBooks Databases

Retrieved on: 
Wednesday, March 24, 2021
Information technology, salesforce.com, Tableau Software, Wallingford, Seattle, Severe acute respiratory syndrome coronavirus, Computing, Application software

LOS ANGELES, March 24, 2021 /PRNewswire/ --DeciBio Analytics, the market intelligence subsidiary of DeciBio Consulting, has launched the 2021 edition of the DxBooks.

Key Points: 
  • LOS ANGELES, March 24, 2021 /PRNewswire/ --DeciBio Analytics, the market intelligence subsidiary of DeciBio Consulting, has launched the 2021 edition of the DxBooks.
  • These clinical diagnostic databases include the Infectious Disease DxBook, the Oncology DxBook, and the SARS-CoV-2 DxBook.
  • DxBooks' web-based Tableau interfaces complement the raw data sets by intuitively facilitating point-and-click data slicing and quick insights.
  • The DxBooks databases are available off-the-shelf on an annual subscription basis or as part of DeciBio Consulting's custom strategic consulting projects.

IDbyDNA Boosts Its Global Metagenomic Respiratory Pathogen/AMR Surveillance Solution to Now Offer Enhanced SARS-CoV-2 Variant Interpretation

Retrieved on: 
Tuesday, March 23, 2021
Sarbecovirus, Zoonoses, Branches of biology, Animal diseases, Articles, Severe acute respiratory syndrome coronavirus, Polymerase chain reaction, COVID-19, Severe acute respiratory syndrome, Human coronavirus HKU1

The widely used PCR and rapid antigen tests cannot detect these variants, allowing the virus to evolve in stealth mode.

Key Points: 
  • The widely used PCR and rapid antigen tests cannot detect these variants, allowing the virus to evolve in stealth mode.
  • Early identification and monitoring of SARS-CoV-2 will help public health officials and researchers better understand the evolving virus.
  • Today, IDbyDNA is announcing significant enhancements to its fully automated data analysis suite for the combined IDbyDNA and Illumina, Inc. Respiratory Pathogen ID/AMR Target Enrichment Panel (RPIP).
  • "The key to managing COVID-19, influenza, and other emerging respiratory infections, is more robust and real-time genomic-level insights into circulating strains.